MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

A review of bevacizumab in the treatment of malignant pleural mesothelioma

Future Oncology 2017 September [Epub ahead of print] [Link]

Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, a monoclonal anti-VEGF antibody, was a rational approach to be tested in MPM. Based on the results of the Phase III IFCT-0701 mesothelioma avastin cisplatin pemetrexed study, cisplatin-pemetrexed-bevacizumab is now the accepted standard in France. The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.

Both comments and trackbacks are currently closed.